Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Shanghai Henlius Biotech stock

2696.HK
CNE100003N76

Price

18.88
Today +/-
-0.00
Today %
-0.14 %
P

Shanghai Henlius Biotech stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Shanghai Henlius Biotech stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Shanghai Henlius Biotech stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Shanghai Henlius Biotech stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Shanghai Henlius Biotech's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Shanghai Henlius Biotech Stock Price History

DateShanghai Henlius Biotech Price
11/19/202418.88 undefined
11/18/202418.91 undefined
11/15/202418.71 undefined
11/14/202418.81 undefined
11/13/202419.20 undefined
11/12/202419.07 undefined
11/11/202419.44 undefined
11/8/202419.41 undefined
11/7/202419.30 undefined
11/6/202419.47 undefined
11/5/202419.61 undefined
11/4/202419.92 undefined
11/1/202420.07 undefined
10/31/202419.91 undefined
10/30/202420.28 undefined
10/29/202420.33 undefined
10/28/202420.00 undefined
10/25/202419.80 undefined
10/24/202419.88 undefined
10/23/202420.10 undefined
10/22/202420.21 undefined

Shanghai Henlius Biotech Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Shanghai Henlius Biotech, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Shanghai Henlius Biotech from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Shanghai Henlius Biotech’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Shanghai Henlius Biotech. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Shanghai Henlius Biotech’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Shanghai Henlius Biotech’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Shanghai Henlius Biotech’s growth potential.

Shanghai Henlius Biotech Revenue, EBIT and net profit per share

DateShanghai Henlius Biotech RevenueShanghai Henlius Biotech EBITShanghai Henlius Biotech Net Income
2026e7.35 B undefined1.17 B undefined309.72 M undefined
2025e6.14 B undefined822.49 M undefined230.71 M undefined
2024e5.82 B undefined708.29 M undefined180.03 M undefined
20235.39 B undefined673.39 M undefined546.02 M undefined
20223.21 B undefined-624.71 M undefined-695.26 M undefined
20211.68 B undefined-874.61 M undefined-984.05 M undefined
2020587.59 M undefined-957.24 M undefined-993.54 M undefined
201990.93 M undefined-837.27 M undefined-875.47 M undefined
20187.42 M undefined-456.46 M undefined-493.69 M undefined
201733.91 M undefined-325.37 M undefined-270.56 M undefined

Shanghai Henlius Biotech Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (B)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20172018201920202021202220232024e2025e2026e
0.030.010.090.591.683.215.395.826.147.35
--78.791,185.71552.22186.5491.0867.837.955.4419.69
54.5528.5721.1168.9968.9173.7472.6467.2863.8153.31
0.0200.020.411.162.373.92000
-270-493-875-993-984-695546180230309
-82.5977.4813.49-0.91-29.37-178.56-67.0327.7834.35
352.72426.6497.16529.57538.84542.02543.37000
----------
Details

Keystats

ⓘ

Revenue and Growth

The Shanghai Henlius Biotech Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Shanghai Henlius Biotech is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (B)TANGIBLE ASSETS (B)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (B)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (B)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (B)LIABILITIES (M)PROVISIONS (B)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (B)SHORT-TERM REC. (B)LONG-T. LIAB. (B)DEFERRED TAXES (M)OTHER LIAB. (B)LONG-T. LIABILITIES (B)DEBT (B)TOTAL CAPITAL (B)
2017201820192020202120222023
             
0.070.982.331.140.710.840.99
19.96.8229.83196.21295.74455.51730.25
96.6851.64118.57205.86133.4552.12134.98
24.6725.2129.87305.22420.11757.31757.36
26.2826.2952.5364.3990.5285.9465.78
0.231.092.661.911.652.192.68
0.460.490.861.441.672.232.65
0000000
0000000
0.771.382.182.943.634.334.51
0000000
20.56130.43206.58149.54223.67170.6164.16
1.252.013.244.535.536.737.23
1.483.095.96.447.178.929.9
             
366.29474.43543.5543.5543.5543.5543.5
0.332.865.745.956.016.056.07
-770.11-1,528.41-2,280.14-3,296.39-4,253.31-4,951.9-4,413.58
-2.8-0.65-0.8-2.57-3.02-7.02-7
0000000
-0.081.843.22.31.642.19
74.285.31240.16298.95383.47713.55544.82
0.030.070.130.270.420.851.06
507.73232.13307.45225.47587.8912.36663.25
0000000
0.60.140.281.191.572.522.8
1.210.530.961.982.9655.07
0.160.390.330.651.051.151.29
0000000
0.190.370.610.620.861.131.35
0.350.760.941.261.922.292.64
1.561.291.93.244.887.297.71
1.483.095.96.447.178.929.9
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Shanghai Henlius Biotech provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Shanghai Henlius Biotech's financial health and stability.

Assets

Shanghai Henlius Biotech's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Shanghai Henlius Biotech must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Shanghai Henlius Biotech after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Shanghai Henlius Biotech's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (B)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (B)NET CHANGE IN EQUITY (B)CASH FLOW FROM FINANCING ACTIVITIES (B)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (B)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
201720182019202020212022
-379-500-874-993-956-693
264282135200277
000000
0.040.30.150.120.511.1
183107196132335298
4344352883114
440001
-134-52-443-60990981
-115-137-500-557-1,131-1,365
-471-735-1,132-1,512-1,681-1,358
-356-598-632-955-5506
000000
0.41-0.280.051.050.730.97
0.152.642.95000
0.541.682.9510.650.86
-15.00-680.00-52.00-54.00-83.00-114.00
000000
-0.060.91.34-1.19-0.960.52
-249.68-189.25-943.73-1,166.58-1,040.8-383.67
000000

Shanghai Henlius Biotech stock margins

The Shanghai Henlius Biotech margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Shanghai Henlius Biotech. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Shanghai Henlius Biotech.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Shanghai Henlius Biotech's sales revenue. A higher gross margin percentage indicates that the Shanghai Henlius Biotech retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Shanghai Henlius Biotech's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Shanghai Henlius Biotech's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Shanghai Henlius Biotech's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Shanghai Henlius Biotech. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Shanghai Henlius Biotech's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Shanghai Henlius Biotech Margin History

Shanghai Henlius Biotech Gross marginShanghai Henlius Biotech Profit marginShanghai Henlius Biotech EBIT marginShanghai Henlius Biotech Profit margin
2026e72.64 %15.93 %4.21 %
2025e72.64 %13.4 %3.76 %
2024e72.64 %12.16 %3.09 %
202372.64 %12.48 %10.12 %
202273.73 %-19.43 %-21.63 %
202168.93 %-51.98 %-58.49 %
202069.01 %-162.91 %-169.09 %
201921.01 %-920.79 %-962.8 %
201827.26 %-6,150.91 %-6,652.55 %
201755.71 %-959.51 %-797.88 %

Shanghai Henlius Biotech Stock Sales Revenue, EBIT, Earnings per Share

The Shanghai Henlius Biotech earnings per share therefore indicates how much revenue Shanghai Henlius Biotech has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Shanghai Henlius Biotech earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Shanghai Henlius Biotech's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Shanghai Henlius Biotech’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Shanghai Henlius Biotech's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Shanghai Henlius Biotech Revenue, EBIT and net profit per share

DateShanghai Henlius Biotech Sales per ShareShanghai Henlius Biotech EBIT per shareShanghai Henlius Biotech Earnings per Share
2026e44.97 undefined0 undefined1.9 undefined
2025e37.57 undefined0 undefined1.41 undefined
2024e35.63 undefined0 undefined1.1 undefined
20239.93 undefined1.24 undefined1 undefined
20225.93 undefined-1.15 undefined-1.28 undefined
20213.12 undefined-1.62 undefined-1.83 undefined
20201.11 undefined-1.81 undefined-1.88 undefined
20190.18 undefined-1.68 undefined-1.76 undefined
20180.02 undefined-1.07 undefined-1.16 undefined
20170.1 undefined-0.92 undefined-0.77 undefined

Shanghai Henlius Biotech business model

Shanghai Henlius Biotech Inc. was founded in 2010 and has since focused on the development of innovative biopharmaceuticals. The company is headquartered in Shanghai, China and has additional locations in Taiwan, the USA, and Europe. The company has developed a wide portfolio of products that are manufactured based on monoclonal antibodies. These antibodies are produced in the human body and can recognize and attack diseased tissue, making them useful for the treatment of various diseases. Shanghai Henlius Biotech Inc.'s business model is based on an extensive research and development process, ranging from the discovery of a new drug to final product approval. The company utilizes advanced technologies and research facilities to develop innovative therapies. The company specializes in the development of biosimilars and novel biopharmaceuticals. Biosimilars are drugs that are structurally similar to already approved biopharmaceuticals but may differ in some characteristics, such as their precise molecular structure. The company has already launched several biosimilars on the market, including those for the treatment of gynecologic cancer, breast cancer, and rheumatoid arthritis. In addition to biosimilars, the company also focuses on the development of novel biopharmaceuticals. These drugs are typically used for the treatment of rare diseases or cancer where there are limited treatment options available. The company has developed several such products, including antibodies for the treatment of lung cancer and bladder cancer. Shanghai Henlius Biotech Inc. has successfully established itself in the Chinese market in recent years but also operates internationally. The company has partnerships with numerous companies in Asia, Europe, and the USA to distribute its products worldwide. Partners include well-known names such as Accord Healthcare, Sandoz, and Pfizer. Overall, Shanghai Henlius Biotech Inc. is a leading player in the biotechnology industry. The company specializes in the development of high-quality biopharmaceuticals and has the capability to develop and bring innovative therapies to the market. Its business model is based on extensive research and development processes, allowing the company to be innovative and successful in a highly competitive market. Shanghai Henlius Biotech is one of the most popular companies on Eulerpool.com.

Shanghai Henlius Biotech SWOT Analysis

Strengths

Shanghai Henlius Biotech Inc has a strong portfolio of innovative biotech products, allowing them to compete effectively in the market.

The company has a talented and experienced team of scientists and researchers who drive the development of high-quality, effective drugs.

Shanghai Henlius Biotech Inc has established strong partnerships with reputable pharmaceutical companies, enabling them to leverage their resources and expand their market reach.

The company has a robust manufacturing infrastructure and distribution network, ensuring efficient production and timely delivery of their products.

Shanghai Henlius Biotech Inc has a solid financial position, allowing them to invest in research and development and further enhance their product pipeline.

Although Shanghai Henlius Biotech Inc has a strong portfolio, they face the challenge of intense competition in the biotech industry.

The company may rely heavily on a few key products, making them vulnerable to fluctuations in demand and market dynamics.

Shanghai Henlius Biotech Inc may have limited market presence in certain regions, restricting their revenue potential.

The company's research and development process may be lengthy and costly, impacting their ability to quickly bring new products to market.

Shanghai Henlius Biotech Inc may lack the same brand recognition and reputation as some of their larger competitors.

The biotech industry is experiencing significant growth, providing Shanghai Henlius Biotech Inc with opportunities to capture a larger market share.

Expansion into emerging markets offers the company potential for increased revenue and access to untapped customer segments.

Shanghai Henlius Biotech Inc can capitalize on advancements in technology and scientific knowledge to develop more innovative and effective drugs.

The increasing demand for personalized medicine presents an opportunity for the company to develop targeted therapies and strengthen their market position.

Strategic collaborations and partnerships with academic institutions and research organizations can enhance Shanghai Henlius Biotech Inc's research capabilities and accelerate product development.

The biotech industry is highly regulated, and changes in regulations and government policies can impact the operations and profitability of Shanghai Henlius Biotech Inc.

Intense competition from both established pharmaceutical companies and emerging startups poses a threat to the company's market share.

The global economic climate and fluctuations in currency exchange rates may affect the affordability and demand for Shanghai Henlius Biotech Inc's products.

Intellectual property infringement and the potential for legal disputes can pose risks to the company's intellectual assets and financial position.

Public perception and concerns around the safety and efficacy of biotech products may impact the reputation and market acceptance of Shanghai Henlius Biotech Inc.

Weaknesses

Although Shanghai Henlius Biotech Inc has a strong portfolio, they face the challenge of intense competition in the biotech industry.

The company may rely heavily on a few key products, making them vulnerable to fluctuations in demand and market dynamics.

Shanghai Henlius Biotech Inc may have limited market presence in certain regions, restricting their revenue potential.

The company's research and development process may be lengthy and costly, impacting their ability to quickly bring new products to market.

Shanghai Henlius Biotech Inc may lack the same brand recognition and reputation as some of their larger competitors.

The biotech industry is experiencing significant growth, providing Shanghai Henlius Biotech Inc with opportunities to capture a larger market share.

Expansion into emerging markets offers the company potential for increased revenue and access to untapped customer segments.

Shanghai Henlius Biotech Inc can capitalize on advancements in technology and scientific knowledge to develop more innovative and effective drugs.

The increasing demand for personalized medicine presents an opportunity for the company to develop targeted therapies and strengthen their market position.

Strategic collaborations and partnerships with academic institutions and research organizations can enhance Shanghai Henlius Biotech Inc's research capabilities and accelerate product development.

The biotech industry is highly regulated, and changes in regulations and government policies can impact the operations and profitability of Shanghai Henlius Biotech Inc.

Intense competition from both established pharmaceutical companies and emerging startups poses a threat to the company's market share.

The global economic climate and fluctuations in currency exchange rates may affect the affordability and demand for Shanghai Henlius Biotech Inc's products.

Intellectual property infringement and the potential for legal disputes can pose risks to the company's intellectual assets and financial position.

Public perception and concerns around the safety and efficacy of biotech products may impact the reputation and market acceptance of Shanghai Henlius Biotech Inc.

Opportunities

The biotech industry is experiencing significant growth, providing Shanghai Henlius Biotech Inc with opportunities to capture a larger market share.

Expansion into emerging markets offers the company potential for increased revenue and access to untapped customer segments.

Shanghai Henlius Biotech Inc can capitalize on advancements in technology and scientific knowledge to develop more innovative and effective drugs.

The increasing demand for personalized medicine presents an opportunity for the company to develop targeted therapies and strengthen their market position.

Strategic collaborations and partnerships with academic institutions and research organizations can enhance Shanghai Henlius Biotech Inc's research capabilities and accelerate product development.

The biotech industry is highly regulated, and changes in regulations and government policies can impact the operations and profitability of Shanghai Henlius Biotech Inc.

Intense competition from both established pharmaceutical companies and emerging startups poses a threat to the company's market share.

The global economic climate and fluctuations in currency exchange rates may affect the affordability and demand for Shanghai Henlius Biotech Inc's products.

Intellectual property infringement and the potential for legal disputes can pose risks to the company's intellectual assets and financial position.

Public perception and concerns around the safety and efficacy of biotech products may impact the reputation and market acceptance of Shanghai Henlius Biotech Inc.

Threats

The biotech industry is highly regulated, and changes in regulations and government policies can impact the operations and profitability of Shanghai Henlius Biotech Inc.

Intense competition from both established pharmaceutical companies and emerging startups poses a threat to the company's market share.

The global economic climate and fluctuations in currency exchange rates may affect the affordability and demand for Shanghai Henlius Biotech Inc's products.

Intellectual property infringement and the potential for legal disputes can pose risks to the company's intellectual assets and financial position.

Public perception and concerns around the safety and efficacy of biotech products may impact the reputation and market acceptance of Shanghai Henlius Biotech Inc.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Shanghai Henlius Biotech Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Shanghai Henlius Biotech historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Shanghai Henlius Biotech shares outstanding

The number of shares was Shanghai Henlius Biotech in 2023 — This indicates how many shares 543.373 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Shanghai Henlius Biotech earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Shanghai Henlius Biotech's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Shanghai Henlius Biotech’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Shanghai Henlius Biotech's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Shanghai Henlius Biotech.

Shanghai Henlius Biotech shareholders

%
Name
Stocks
Change
Date
26.77429 % Henlius Biopharmaceuticals, Inc.43,756,960012/31/2023
19.78296 % Fosun International Ltd32,331,100-3,192,3396/30/2024
15.97519 % BlackRock Institutional Trust Company, N.A.26,108,09826,108,0988/7/2024
7.98870 % Qatar Investment Authority13,055,859-1,157,8415/9/2024
6.22546 % BlackRock Asset Management Ireland Limited10,174,20010,174,2008/7/2024
3.23384 % Golden Valley Global Ltd.5,285,032383,1009/3/2024
1.75615 % Loyal Valley Capital2,870,052-1,383,7489/3/2024
1.47507 % Liu (Scott Shi-Kau)2,410,695012/31/2023
0.09356 % State Street Global Advisors (US)152,90009/30/2024
0.09246 % Dimensional Fund Advisors, L.P.151,10008/31/2024
1
2
3

Shanghai Henlius Biotech Executives and Management Board

Mr. Wenjie Zhang(55)
Shanghai Henlius Biotech Executive Chairman of the Board (since 2019)
Compensation 28.04 M
Dr. Lik Yuen Chan(53)
Shanghai Henlius Biotech Non-Executive Independent Director
Compensation 249,000
Mr. Tak Young So(51)
Shanghai Henlius Biotech Non-Executive Independent Director
Compensation 249,000
Dr. Ruilin Song(59)
Shanghai Henlius Biotech Non-Executive Independent Director
Compensation 249,000
Dr. Guoping Zhao(73)
Shanghai Henlius Biotech Non-Executive Independent Director
Compensation 249,000
1
2
3
4

Most common questions regarding Shanghai Henlius Biotech

What values and corporate philosophy does Shanghai Henlius Biotech represent?

Shanghai Henlius Biotech Inc represents a set of core values and corporate philosophy. The company aims to prioritize innovation, quality, and patient-centricity in the field of biotechnology. With a strong focus on research and development, Henlius strives to bring affordable and accessible biopharmaceutical products to improve treatment outcomes for patients worldwide. The company values transparency, integrity, and collaboration, believing in the importance of ethical business practices and maintaining trust with stakeholders. Shanghai Henlius Biotech Inc is committed to continuously advancing medical advancements to benefit global healthcare.

In which countries and regions is Shanghai Henlius Biotech primarily present?

Shanghai Henlius Biotech Inc is primarily present in China, with a focus on the domestic market. Being headquartered in Shanghai, the company strategically operates within the country to leverage the vast opportunities and resources available. With its strong presence in China, Shanghai Henlius Biotech Inc aims to serve the growing demand for biotech products and contribute to the advancement of the healthcare industry in the region. As a leading biopharmaceutical company, Shanghai Henlius Biotech Inc continues to expand its footprint and explore potential collaborations and market opportunities both within China and internationally.

What significant milestones has the company Shanghai Henlius Biotech achieved?

Shanghai Henlius Biotech Inc, a leading biopharmaceutical company, has accomplished significant milestones in its journey. The company has successfully developed and commercialized a portfolio of innovative, high-quality therapeutics, particularly in the field of oncology. Henlius became the first company in China to obtain the Marketing Authorization Approval (MAA) for a monoclonal antibody biosimilar, setting a new benchmark in the industry. With a strong focus on research and development, the company has also achieved remarkable progress in advancing its pipeline products. Shanghai Henlius Biotech Inc continues to make strides in improving patient lives through its cutting-edge biotechnological breakthroughs.

What is the history and background of the company Shanghai Henlius Biotech?

Shanghai Henlius Biotech Inc is a renowned biotechnology company based in Shanghai, China. Established in 2010, the company focuses on the research, development, and commercialization of innovative and high-quality biologics. With a strong commitment to healthcare advancement, Shanghai Henlius Biotech Inc has made significant contributions to the biopharmaceutical industry. The company has a diverse portfolio of products that encompass monoclonal antibodies, biosimilars, and next-generation biotherapeutics. Shanghai Henlius Biotech Inc has also established strategic partnerships with domestic and international pharmaceutical companies to enhance its global presence. With its rich history and dedication to improving patients' lives, Shanghai Henlius Biotech Inc has emerged as a leading player in the biotech industry.

Who are the main competitors of Shanghai Henlius Biotech in the market?

Some of the main competitors of Shanghai Henlius Biotech Inc in the market include domestic pharmaceutical companies such as BeiGene Ltd., Hutchison China MediTech Ltd. (Chi-Med), Jiangsu Hengrui Medicine Co., Ltd., and Innovent Biologics Inc. These companies also operate in the biotechnology sector and compete in areas such as research and development of innovative drugs, manufacturing, and commercialization of biopharmaceutical products.

In which industries is Shanghai Henlius Biotech primarily active?

Shanghai Henlius Biotech Inc is primarily active in the biotechnology industry.

What is the business model of Shanghai Henlius Biotech?

The business model of Shanghai Henlius Biotech Inc revolves around the development, manufacturing, and commercialization of innovative biopharmaceutical products. As a leading biotech company in China, Henlius focuses on the research and production of high-quality monoclonal antibodies and biosimilars for the treatment of various diseases, including cancer. By utilizing advanced technology and comprehensive quality control systems, Henlius aims to provide cost-effective and accessible healthcare solutions to patients in need. With its strong R&D capabilities and strategic partnerships, Shanghai Henlius Biotech Inc strives to make significant contributions to the biopharmaceutical industry in both domestic and international markets.

What is the P/E ratio of Shanghai Henlius Biotech 2024?

The Shanghai Henlius Biotech P/E ratio is 56.98.

What is the P/S ratio of Shanghai Henlius Biotech 2024?

The Shanghai Henlius Biotech P/S ratio is 1.76.

What is the Quality Investing of Shanghai Henlius Biotech?

The Quality Investing for Shanghai Henlius Biotech is 3/10.

What is the revenue of Shanghai Henlius Biotech 2024?

The expected Shanghai Henlius Biotech revenue is 5.82 B CNY.

How high is the profit of Shanghai Henlius Biotech 2024?

The expected Shanghai Henlius Biotech profit is 180.03 M CNY.

What is the business model of Shanghai Henlius Biotech

Shanghai Henlius Biotech Inc is a Chinese company that specializes in the development, production, and marketing of innovative biopharmaceuticals. Henlius has built a comprehensive portfolio of biosimilars, novel antibodies, and cell therapies for the treatment of cancer and other serious diseases. One of Henlius's core businesses is the development and production of biosimilars, which can be introduced to the market as cost-effective alternatives to expensive biopharmaceuticals. The company has a team of over 600 employees, including over 200 scientists, who focus on the research and development of biosimilars. The biosimilars are developed and produced in close collaboration with top international partners such as Pfizer, Boehringer Ingelheim, Accord Healthcare, and others. Another important business area for Henlius is the development of novel antibodies for the treatment of cancer. These antibodies specifically target cancer cells and can mobilize the body's immune system to fight cancer. Henlius has several antibody candidates in clinical development and plans to introduce products soon. Henlius is also involved in cell therapy, an emerging field of biotechnology where a patient's own cells are used for the treatment of diseases. Cell therapy can be used for the treatment of cancer, autoimmune diseases, and other conditions. Henlius has several cell therapy products in clinical development and collaborates closely with leading academics and institutions to advance the development of these products. Henlius's business model is based on the combination of research, development, and production of novel biopharmaceuticals. Henlius has built a comprehensive platform for the development of biosimilars, novel antibodies, and cell therapy products, supported by experienced scientists and a dedicated leadership team. Henlius's products have the potential to improve the lives of millions of patients worldwide and make the company a key player in the biopharmaceutical market. Overall, Henlius has developed a wide range of products and services to meet the needs of patients and the market. The company relies on collaboration with leading partners and institutions to accelerate the development and production of biopharmaceuticals. Henlius has ambitious plans for the future and is likely to play a significant role in the development of biosimilars, novel antibodies, and cell therapies.

What is the Shanghai Henlius Biotech dividend?

Shanghai Henlius Biotech pays a dividend of 0 CNY distributed over payouts per year.

How often does Shanghai Henlius Biotech pay dividends?

The dividend cannot currently be calculated for Shanghai Henlius Biotech or the company does not pay out a dividend.

What is the Shanghai Henlius Biotech ISIN?

The ISIN of Shanghai Henlius Biotech is CNE100003N76.

What is the Shanghai Henlius Biotech ticker?

The ticker of Shanghai Henlius Biotech is 2696.HK.

How much dividend does Shanghai Henlius Biotech pay?

Over the past 12 months, Shanghai Henlius Biotech paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Shanghai Henlius Biotech is expected to pay a dividend of 0 CNY.

What is the dividend yield of Shanghai Henlius Biotech?

The current dividend yield of Shanghai Henlius Biotech is .

When does Shanghai Henlius Biotech pay dividends?

Shanghai Henlius Biotech pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Shanghai Henlius Biotech?

Shanghai Henlius Biotech paid dividends every year for the past 0 years.

What is the dividend of Shanghai Henlius Biotech?

For the upcoming 12 months, dividends amounting to 0 CNY are expected. This corresponds to a dividend yield of 0 %.

In which sector is Shanghai Henlius Biotech located?

Shanghai Henlius Biotech is assigned to the 'Health' sector.

Wann musste ich die Aktien von Shanghai Henlius Biotech kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Shanghai Henlius Biotech from 11/20/2024 amounting to 0 CNY, you needed to have the stock in your portfolio before the ex-date on 11/20/2024.

When did Shanghai Henlius Biotech pay the last dividend?

The last dividend was paid out on 11/20/2024.

What was the dividend of Shanghai Henlius Biotech in the year 2023?

In the year 2023, Shanghai Henlius Biotech distributed 0 CNY as dividends.

In which currency does Shanghai Henlius Biotech pay out the dividend?

The dividends of Shanghai Henlius Biotech are distributed in CNY.

All fundamentals about Shanghai Henlius Biotech

Our stock analysis for Shanghai Henlius Biotech Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Shanghai Henlius Biotech Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.